Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care

Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care

New data reveal sharp growth in Ozempic prescribing across the country, reflecting the rising demand for GLP-1 therapies

Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

New research suggests the clinical benefits of GLP-1 therapies have yet to translate into near-term medical cost savings

Only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years

Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* aprocitentan Tryvio® Idosia Difficult-to-control or resistant hypertension Oral March budesonide Eohilia™...

The 2026 Medical Pharmacy Trend Report: Part 1– Payer Survey reflects Prime Therapeutics’ long standing commitment to delivering trusted, data driven perspectives that shape the industry...

Prime Therapeutics’ Clinical Insights is your trusted resource for timely, evidence based perspectives on emerging therapies and managed care strategy. The Summer 2025 issue focuses on metabolic...

Industry experts share new insights from PBM industry, including GLP-1 weight-loss drugs, biosimilars and rising pharmaceutical costs

Prime Therapeutics clinical experts shared insights on the specialty drug pipeline at recent industry event

Real-world data reveal a persistent challenge: helping patients maintain GLP-1 treatment long enough to realize its full benefits

Lassen, chief clinical officer at Prime Therapeutics/Magellan Rx, shares insights on GLP-1 weight-loss drugs and evidence-based approaches to providing the kind of care we’d want for our loved ones.

From new treatment options for dry eye disease to type 2 diabetes, here are a few of the top U.S. Food and Drug Administration drug decisions expected this year

Generic Name Brand Name Brand Manufacturer Indication Approval Month* chikungunya vaccine, live Ixchiq® Valneva Austria Prevention of disease caused by Chikungunya virus November meningococcal...

Editor-In-Chief: Maryam Tabatabai, PharmD Executive Editor: Anna Schreck Bird, PharmD Deputy Editors: Erik Hamel, PharmD; Olivia Pane, PharmD, CDCES A retrospective propensity score-matched cohort...

The event emphasizes additional measures for obesity therapy.

Prime Therapeutics researchers share more about award-winning real-world research

Novartis submitted an application to the FDA in 2Q 2025 for an intrathecal formulation (OAV101IT) of their one-time gene therapy onasemnogene abeparvovec (OAV101IT) for the treatment of spinal...

Maryam Tabatabai, PharmD, associate vice president of clinical information, shares more about how cell and gene therapies are transforming the treatment landscape, and how payers and providers can...

Critical updates in an ever-changing environment

Learn with Biosimilar Basics. Part 2 covers biosimilar naming conventions and other nomenclature including common drug pipeline content acronyms.

Drug pipeline for October 2026 At Prime Therapeutics (Prime), we have positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade relations teams keep a keen eye on...

Critical updates in an ever-changing environment.

Zolgensma, which was FDA approved in May 2019, is administered as an intravenous (IV) infusion, with dosing based on patient weight, in pediatric patients under 2 years of age with SMA caused by...

A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the use of GLP-1 medications to treat obesity when paired...

Editorial team The American College of Physicians (ACP) has released a clinical practice guideline on use of pharmacological treatment for prevention of episodic migraine, defined as one to 14...

Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Tividenofusp alfa (DNL310) AstraZeneca IV a fusion protein ERT...

Shortage Updates Eli Lilly’s tirzepatide (Zepbound) is reported as currently available in all strengths, as is the T2DM formulation of tirzepatide (Mounjaro). Additionally, all strengths of Novo...

Clinical deep dive Disease state overview SMA is a rare, debilitating, hereditary disease characterized by progressive motor function decline and muscular atrophy. Most commonly, SMA results from a...

What to expect at Academy of Managed Care Pharmacy (AMCP) Nexus 2023

This monthly approval update provides a review of newly approved specialty drugs, recent drug launches, generic updates, new indications and news of note on drugs in the approval process.

Pharmacy Practice News, originally published by Specialty Pharmacy Continuum

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes—evidenced by successful studies in therapeutic areas like cardiovascular and...

Acetaminophen (Tylenol) update The United States (U.S.) Food and Drug Administration (FDA) announced the initiation of a safety label change for products containing acetaminophen (Tylenol, other...

Want more information on this topic and more from our KOLs? On June 15, 2025, Sarepta, the manufacturer of Elevidys, issued a press release that announced a safety update for Elevidys and steps to...

BEHAVIORAL HEALTH CORNER The Psychopharmacologic Drugs Advisory Committee will convene on June 4, 2024 to discuss an NDA for midomafetamine (MDMA) capsules from Lykos Therapeutics. The psychedelic...

Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status DNL126 Denali Therapeutics  IV SGSH RT using ETVto deliver SGSH...

Specialty May 23, 2025 – meningococcal (groups A, C, Y, W) conjugate vaccine (MenQuadfi) Sanofi Pasteur; meningococcal vaccine for active immunization Expanded indication: for the prevention of...

Editorial team The American Diabetes Association (ADA) has released the 2025 Standards of Care in Diabetes. In addition to new recommendations on nutrition and technology, additional guidance was...

Aug. 14, 2026 PUBLICATIONS FDA Decisions Expected: September 2026 Your monthly synopsis of new drugs expected to hit the market Drug pipeline for September 2026 At Prime Therapeutics (Prime), we...

Clinical News EDITOR-IN-CHIEF: Maryam Tabatabai, PharmD EXECUTIVE EDITOR: Anna Schreck Bird, PharmD DEPUTY EDITORS: Erik Hamel, PharmD; Olivia Pane, PharmD, CDCES HCl = hydrochloride HCP = health...

The American Journal of Managed Care (AJMC): The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still...

The American Academy of Pediatrics (AAP) published its first clinical practice guideline on opioid prescribing for acute pain management in children and adolescents in outpatient settings. The...

Clinical deep dive Disease State Overview Metachromatic leukodystrophy (MLD) is a rare, autosomal recessive, genetic, eventually fatal lysosomal storage disorder. MLD is caused by mutations in the...

publications Trending Topics & Drug Approvals: July 2026 Your source for the latest drug information highlights Specialty Glossary June 17, 2026 — azilsartan medoxomil (Edarbi) Lupin...

Managed Healthcare Executive: Use of GLP-1 drugs and weight-loss care management programs need to focus on adherence and persistency for better health outcomes, suggests Prime...

The Fall 2025 Prime Therapeutics Report delivers a comprehensive look at the evolving oncology landscape—from rising cancer rates in younger populations to the expanding role of...

March 27, 2026 – vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) Vertex; combination of deutivacaftor (a CFTR potentiator) and tezacaftor/vanzacaftor (CFTR correctors); expanded indication is based...

July 14, 2025 Author: Abby Kim, PharmD, BCOP The DESTINY-Breast09 trial marked a pivotal moment in the treatment of HER2-positive metastatic breast cancer, offering the first major advancement in...

The American Thoracic Society, CDC, European Respiratory Society and Infectious Diseases Society of America (IDSA) have published updated clinical practice guidelines for tuberculosis (TB)...

The Prime Therapeutics Report is your trusted source for the latest in managed care strategies, specialty drug trends and payer-focused insights. The Summer 2025 issue features a cover story on HIV...

July 15, 2026 publications Summer 2026 Prime Therapeutics Report Explore timely specialty insights for managed care, including autoimmune biosimilars, policy developments, pipeline activity,...

Tab 1 BEHAVIORAL HEALTH CORNER WEIGHT MANAGEMENT CORNER Clinical News EDITOR-IN-CHIEF: Maryam Tabatabai, PharmD EXECUTIVE EDITOR: Anna Schreck Bird, PharmD DEPUTY EDITORS: Erik Hamel, PharmD;...

WEIGHT MANAGEMENT CORNER The American Heart Association (AHA) has published a Presidential Advisory forecasting the extent of cardiovascular disease (CVD) and stroke expected in the U.S. through...

The content in this publication is not a substitute for professional medical advice. For questions regarding any medical condition or if you need medical advice, please contact your health care...

SAVINGS PER CASE $11,500 An employer group with 7,000 lives implemented HighTouchRx. They saw savings of $194,300, with HighTouchRx providing an ROI of 5:1.4 Since its launch, HighTouchRx has saved...